Squarepoint Ops LLC Invests $35,000 in Curis, Inc. (NASDAQ:CRIS)

Squarepoint Ops LLC purchased a new position in shares of Curis, Inc. (NASDAQ:CRIS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,564 shares of the biotechnology company’s stock, valued at approximately $35,000. Squarepoint Ops LLC owned approximately 0.14% of Curis at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CRIS. Millennium Management LLC raised its holdings in Curis by 92.6% in the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 12,287 shares during the last quarter. Geode Capital Management LLC raised its holdings in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after acquiring an additional 17,820 shares during the last quarter. M28 Capital Management LP raised its holdings in Curis by 23.5% in the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 99,108 shares during the last quarter. CM Management LLC raised its holdings in Curis by 83.3% in the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Samsara BioCapital LLC acquired a new position in Curis in the 4th quarter valued at $607,000. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Wall Street Analysts Forecast Growth

CRIS has been the subject of a number of research analyst reports. Wall Street Zen initiated coverage on Curis in a report on Friday, May 16th. They set a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Curis in a report on Monday, May 19th.

Curis Stock Up 2.4%

Shares of NASDAQ CRIS opened at $2.51 on Wednesday. The firm’s 50-day moving average price is $1.85 and its two-hundred day moving average price is $2.74. Curis, Inc. has a 52-week low of $1.02 and a 52-week high of $9.02. The stock has a market capitalization of $26.26 million, a P/E ratio of -0.32 and a beta of 3.69.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.14) by ($0.11). Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%. The firm had revenue of $2.38 million during the quarter, compared to analyst estimates of $2.37 million. During the same quarter in the previous year, the business posted ($2.05) EPS. As a group, equities research analysts expect that Curis, Inc. will post -7.12 earnings per share for the current year.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.